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Abstract
Arginine vasopressin (AVP) is released from the posterior pituitary and controls water homeostasis. AVP binding to
vasopressin V2 receptors (V2Rs) located on kidney collecting duct epithelial cells triggers activation of Gs proteins, leading
to increased cAMP levels, trafficking of aquaporin-2 water channels, and consequent increased water permeability and
antidiuresis. Typically, loss-of-function V2R mutations cause nephrogenic diabetes insipidus (NDI), whereas gain-of-function
mutations cause nephrogenic syndrome of inappropriate antidiuresis (NSIAD). Here we provide further characterization of
two mutant V2Rs, R181C and M311V, reported to cause complete and partial NDI respectively, together with a V266A
variant, in a patient diagnosed with NSIAD. Our data in HEK293FT cells revealed that for cAMP accumulation, AVP was about
500- or 30-fold less potent at the R181C and M311V mutants than at the wild-type receptor respectively (and about 4000-
and 60-fold in COS7 cells respectively). However, in contrast to wild type V2R, the R181C mutant failed to increase inositol
phosphate production, while with the M311V mutant, AVP exhibited only partial agonism in addition to a 37-fold potency
decrease. Similar responses were detected in a BRET assay for b-arrestin recruitment, with the R181C receptor unresponsive
to AVP, and partial agonism with a 23-fold decrease in potency observed with M311V in both HEK293FT and COS7 cells.
Notably, the V266A V2R appeared functionally identical to the wild-type receptor in all assays tested, including cAMP and
inositol phosphate accumulation, b-arrestin interaction, and in a BRET assay of receptor ubiquitination. Each receptor was
expressed at comparable levels. Hence, the M311V V2R retains greater activity than the R181C mutant, consistent with the
milder phenotype of NDI associated with this mutant. Notably, the R181C mutant appears to be a Gs protein-biased
receptor incapable of signaling to inositol phosphate or recruiting b-arrestin. The etiology of NSIAD in the patient with
V266A V2R remains unknown.
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Introduction
Arginine vasopressin (AVP) is released from the posterior
pituitary and controls water balance homeostasis [1–3]. AVP,
binding to arginine vasopressin V2 receptors (V2R) located on the
basolateral membrane of kidney collecting duct epithelial cells,
triggers activation of Gs proteins, leading to increased cAMP
levels, and activation of Protein Kinase A [1–3]. This in turn
causes trafficking of aquaporin-2 water channels to the apical
membrane of collecting duct cells, resulting in increased water
permeability and antidiuresis [1–3].
The V2R is a 7-transmembrane spanning G protein-coupled
receptor (GPCR) [4,5]. Typically, loss-of-function (in terms of
cAMP signaling) V2R mutations cause nephrogenic diabetes
insipidus (NDI), characterized by an inability to concentrate urine
resulting in excessive urine production, dehydration and thirst
[2,3]. Administration of exogenous AVP fails to restore normal
water balance [2,3]. In contrast, gain-of-function mutations cause
nephrogenic syndrome of inappropriate antidiuresis (NSIAD),
characterized by inappropriately concentrated urine resulting in
excessive sodium excretion, low plasma sodium concentration, and
low serum osmolality [6]. A key feature is the absence of detectable
levels of AVP in serum, whereas the closely related syndrome of
inappropriate antidiuretic hormone secretion (SIADH) is typically
associated with measurably elevated AVP levels and consequent
V2R hyperactivity [6,7].
There are now more than 200 different V2R mutations known
to cause NDI [8], but only three that cause NSIAD [6,9]. This is
not surprising considering that many changes to a protein
structure can result in impaired function, whereas a single point
mutation able to constitutively activate a receptor is much more
rare. Interestingly, the two opposing phenotypes of NDI and
NSIAD can both result from distinct mutations at R137, which is
present within the conserved DRY/H motif of the V2R, a region
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critical for stabilizing the receptor in either inactive or active
conformations [10,11]. Substitution of R137 with H results in NDI
due to an inability of this mutant receptor to stimulate cAMP
production [12]. Whether the loss-of-function is primarily due to
G protein uncoupling, reduced forward trafficking and/or
constitutive internalization is a matter of debate, and it is not
inconceivable that all of these aspects of receptor pharmacology
play a role in the overall phenotype [13,14]. In contrast,
substitution of the same residue with C or L favors constitutive
activation and cAMP production, causing NSIAD [6]. Notably,
both R137H and R137C/L mutants recruit b-arrestin constitu-
tively and are constitutively internalized [13–16]. In contrast, the
NSIAD-causing F229V mutation, although resulting in constitu-
tive cAMP activation, does not result in constitutive b-arrestin
interaction. Instead, this receptor is able to recruit b-arrestin in a
ligand-dependent manner similar to that observed with wild-type
V2R, indicating a degree of biased coupling [9].
Correct protein folding and trafficking to the plasma membrane
are critical for V2R function. Indeed, it is thought that the
majority of disease-causing mutations of the V2R, especially those
associated with NDI, result in significant intracellular retention of
the receptor due to a failure to pass quality control systems of the
endoplasmic reticulum and early secretory pathway [2,17,18].
In this study we further characterize two previously reported
mutations of the V2R from patients with NDI, R181C [19–25]
and M311V [25], and a third potential mutation (V266A) from a
patient with a putative diagnosis of NSIAD. V266A has been
previously reported in combination with a nonsense mutation
(W200X/V266A) in a patient with NDI [26], but mutation of
V266A alone by those authors had no effect on cAMP
accumulation (Emax or EC50), ELISA studies or radioligand
binding. However, inositol phosphate production, b-arrestin
interaction and receptor ubiquitination were not assessed. In the
more recent case of a patient with symptoms of NSIAD, including
hyponatremia and low ADH levels that presented during infancy,
no variation in V2R was identified other than V266A. None of the
patient’s immediate family was clinically affected and as they
declined genetic testing, unfortunately it is not known if they also
possessed the same variation in V2R.
We have found that for the R181C and M311V mutant
receptors, the degree of receptor activity lost (for cAMP, inositol
phosphate accumulation and b-arrestin recruitment) correlated
with the severity of disease. However, with the assays we have
utilized, we could find no functional difference between wild-type
and V266A receptor, even for inositol phosphate accumulation, b-
arrestin interaction and receptor ubiquitination. Hence the
etiology of NSIAD in this patient remains uncertain. Most
interestingly, our analysis also revealed that R181C acts as a Gs
protein-biased receptor, unable to couple to b-arrestin or stimulate
inositol phosphate production, yet retaining some ability to
increase intracellular cAMP.
Materials and Methods
Ethics Statement
The R181C and M311V mutations have been published
previously [19–25]. We consulted the Stanford University
Institutional Review Board (IRB) and they stated, in accordance
with U.S. Code of Federal Regulations Title 45 part 46, that the
V266A case should not be part of a protocol. V2R gene
sequencing for the patient with the V266A variant was performed
as a diagnostic test in order to guide clinical care and was
performed in a CLIA approved clinical laboratory, with the
sequence result being reported from the CLIA laboratory. The
clinical laboratory also obtained written consent from the patient
prior to performing genetic testing. There were no patient samples
used in any of the research experiments presented in this
manuscript.
Materials
Wild-type and mutant HA-tagged V2R and V2R/Rluc8 cDNA
constructs were generated by PCR amplification of receptor
cDNA (with appropriate site-directed mutagenesis) and ligated
into pcDNA3 containing the corresponding expression vectors, in
a manner similar to that described previously [13]. Rluc8 cDNA
was kindly provided by Andreas Loening and Sanjiv Gambhir
(Stanford University, CA) [27]. Vasopressin receptor 2 (V2R)/
Rluc8 was generated as described previously [13,16]. The b-
arrestin2/Venus cDNA construct was prepared previously [13]
from pcC2-Venus kindly provided by Atsushi Miyawaki (RIKEN
Brain Science Institute, Wako-city, Japan). Ubiquitin K48,63A/
Venus was prepared as described [28]. Arginine Vasopressin
(AVP) was from Sigma-Aldrich.
Cell Culture and Transfection
HEK293FT (Life Technologies) and COS7 (ATCC) cells were
maintained at 37uC in 5% CO2 and Dulbecco’s modified Eagle’s
medium (DMEM) containing 0.3 mg/ml glutamine, 100 IU/ml
penicillin and 100 mg/ml streptomycin (Gibco) supplemented with
10% foetal calf serum (FCS). HEK293FT cell medium included
400 mg/ml Geneticin (Gibco). Transient transfections were carried
out 24 h after seeding 550,000 HEK293FT or 75,000 COS7 cells
per well of a 6-well plate. Genejuice (Novagen) transfection
reagent was used according to the manufacturer’s instructions.
Cells were harvested 24 h later using 0.05% Trypsin-EDTA
(Gibco), and re-plated into 96-well plates at a density of 100,000
cells per well (HEK293FT) or 15,000 cells per well (COS7) in
phenol red free DMEM containing 5% FCS, 16–18 hours prior to
assay.
BRET Assays
HEK293FT or COS7 cells were transiently transfected with
cDNA encoding wild-type or mutant V2R fused to Rluc8 (V2R/
Rluc8) and b-arrestin2 fused to Venus (b-arrestin2/Venus). In one
set of experiments, cells were transfected with V2R/Rluc8
constructs and a mutant ubiquitin (ubiquitin K48,63A) fused to
Venus (ubiquitin/Venus). This mutant is reported to have a
reduced capacity for poly-ubiquitin chain formation, thereby
avoiding the potential for multiple acceptor moieties causing
quenching or interference phenomena [29]. HEK293FT cells
were transfected with 0.1 mg/well of V2R/Rluc8 and 0.3 mg/well
of b-arrestin2/Venus or ubiquitin/Venus, whereas COS7 cells
were transfected with 0.2 and 0.6 mg/well, respectively. Cells were
harvested as above, plated into white 96 well plates (Nunc) and
incubated in serum free, phenol red free DMEM at 37uC, 5%
CO2 for 2 h with 30 mM EnduRen (Promega) to ensure substrate
equilibrium was reached. BRET measurements were taken at
37uC using the VICTOR Light plate reader with Wallac 1420
software (PerkinElmer). Filtered light emissions were sequentially
measured at 400–475 and 520–540 nm. The BRET signal was
calculated by subtracting the ratio of 520–540 nm emission over
400–475 nm emission for a vehicle-treated cell sample from the
same ratio for a second aliquot of the same cells treated with
agonist, as described previously [30,31]. In this calculation, the
vehicle-treated cell sample represents the background, eliminating
the requirement for measuring a donor-only control sample
[30,31].
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Measurement of Fluorescence
Cells were transfected as above, harvested, and replated into
black 96-well plates (PerkinElmer). Fluorescence was measured on
an EnVision 2102 multilabel plate reader (PerkinElmer) using a
485/14 excitation filter, 535/25 emission filter and D505 mirror.
Measurement of cyclic adenosine monophosphate
(cAMP) production using homogeneous time-resolved
fluorescence (HTRF)
Intracellular cAMP levels were measured using a HTRF cAMP
dynamic 2 assay kit (CisBio Bioassays, Bagnol sur Ceze, France).
Cells were transfected as described above and seeded into white
96-well microplates (Nunc) 24 h prior to assay. Cell media was
removed by aspiration and replaced with 40 ml stimulation buffer
(0.5 mM IBMX, 5 mM HEPES, 0.1% BSA in Hank’s Balanced
Salt Solution; Life Technologies) containing agonists as indicated.
Cells were incubated for 30 min at 37uC and then lysed by
addition of 12.5 ml of the supplied conjugate-lysis buffer containing
d2-labeled cAMP, followed by 12.5 ml of conjugate-lysis buffer
containing terbium cryptate-labeled anti-cAMP antibody, both
reconstituted according to the manufacturer’s instructions. Plates
were incubated for 1 h at room temperature and time-resolved
fluorescence signals were measured at 620 and 665 nm, respec-
tively, 50 ms after excitation at 337 nm using an EnVision 2102
plate reader (PerkinElmer).
Measurement of D-myo-inositol-1-phosphate (IP1)
production using homogeneous time-resolved
fluorescence (HTRF)
Intracellular IP1 levels were measured using a HTRF IP-One
Tb assay kit (CisBio Bioassays, Bagnol sur Ceze, France). Cells
were transfected as described above and seeded into white 96-well
microplates (Nunc) 24 h prior to assay. Cell media was removed
by aspiration and replaced with 40 ml stimulation buffer (as
supplied, including 50 mM LiCl) containing agonists as indicated.
Cells were incubated for 30 min at 37uC and then lysed by
addition of 12.5 ml of the supplied conjugate-lysis buffer containing
d2-labeled IP1, followed by 12.5 ml of conjugate-lysis buffer
containing terbium cryptate-labeled anti-IP1 antibody, both
reconstituted according to the manufacturer’s instructions. Plates
were incubated for 1 h at room temperature and time-resolved
fluorescence signals were measured at 620 and 665 nm, respec-
tively, 50 ms after excitation at 337 nm using an EnVision 2102
plate reader (PerkinElmer).
Quantification of cell surface receptor expression
Cell surface HA-tagged V2Rs were quantified by fluorescence
microscopy using an automated system for image acquisition (IN
Cell Analyzer 1000; GE Healthcare) and validated algorithms for
image analysis [32,33]. Briefly, COS7 cells were seeded in a 6-well
plate (75,000 cells/well) and transiently transfected the next day
with 1 mg HA-tagged V2R cDNA. Cells were harvested 24 h later
and seeded into black 96-well plates (Greiner; 8000 cells/well in
triplicate wells) for 16–18 h prior to staining. Cell surface receptor
staining was performed on live intact cells by incubation with
primary antibody (rabbit polyclonal anti-HA (Sigma-Aldrich)
diluted 1:1000 in DMEM with 1% BSA) for 1 h at 4uC. Cells
were then washed with ice-cold phosphate-buffered saline (PBS),
fixed (2% paraformaldehyde in PBS for 30 min), and permeabi-
lized (0.1% Triton X-100 in PBS for 10 min). Cells were washed
three times, blocked (1 h in PBS containing 0.1% Triton X-100
and 1% BSA), and incubated for 1 h with secondary antibody
(Alexa Fluor 546-conjugated goat anti-rabbit IgG at 1:400 in PBS
with 0.1% Triton X-100 and 1% BSA). Nuclei were stained using
Hoechst 33258 (1 mM, 20 min). Images were acquired, collecting
four fields per well with a 106objective and triple band filter set to
obtain images of 100–1000 cells (per well) in a total imaged area of
2.4 mm2. Image analysis was performed with IN Cell Workstation
3.7 software (GE Healthcare) using a Dual Area Object Analysis
algorithm and a filter to define the proportion of positively stained
cells (cell surface HA-V2R staining .10% above background). A
cell surface expression index was then calculated by multiplying
the proportion of stained cells (% positive cells) by their mean
fluorescence intensity in arbitrary fluorescence units, as described
[32,33].
Data Presentation and Statistical Analysis
Data were analyzed using Prism 5 graphing software (Graph-
Pad). Sigmoidal curves were fitted to the dose-response data using
non-linear regression. Statistical analysis of pEC50 values was
carried out using one-way ANOVA followed by Tukey’s multiple
comparison post-test.
Results
V2R signaling to cAMP and functional validation of the
V2R/Rluc8 fusion protein
The V2R couples to Gs protein, thereby activating adenylate
cyclase and increasing intracellular cAMP. Accordingly, we tested
the ability of the three mutant receptors to increase cAMP levels
using a homogenous time-resolved fluorescence (HTRF) assay
(Figure 1). Treatment of transiently transfected HEK293FT cells
with AVP caused a robust dose-dependent increase in cAMP
(Figure 1A), with particularly high potency for the wild-type and
V266A mutant receptors, the pEC50 values of which were not
significantly different (Table 1). In contrast, AVP was 29- or 427-
fold less potent in cells transfected with M311V or R181C HA-
V2R respectively (Table 1). Next, we tested for the ability of
Rluc8-tagged V2R to couple to Gs in the same cell line (Figure 1B),
as it is important to check that the addition of a BRET tag does
not compromise normal receptor function [34,35]. Again, AVP
caused a dose-dependent increase in cAMP, and for each receptor,
potency was comparable to that obtained with the HA-tagged
V2R (Table 1). Furthermore, the ligand-induced b-arrestin
recruitment shown below provides additional validation of V2R/
Rluc8 functionality. We also tested whether a different cellular
background influenced the effect of the mutations on cAMP
signaling. No significant difference in potency was observed
between wild-type and V266A mutant receptors expressed in
COS7 cells compared to the HEK293FT cell line. Furthermore, a
significantly lower (60-fold) AVP potency was again observed with
M311V and significantly lower still with R181C (3890-fold lower
than wild-type). Indeed, expression of the R181C receptor in
COS7 cells resulted in a significantly lower potency of AVP
compared to its expression in HEK293FT cells (Table 1).
Effect of V2R mutation on IP1 accumulation
Although the V2R predominantly signals through Gs, this
receptor is also known to couple to the Gq class of G-proteins,
activate phospholipase C and increase intracellular Ca2+ [36,37].
Accordingly, we used a HTRF assay of IP1 accumulation (a
downstream metabolite of inositol 1,4,5-trisphosphate; IP3) to test
V2R signaling through this pathway (Figure 2). Addition of AVP
to transfected HEK293FT cells caused a robust dose-dependent
increase in IP1 for the wild-type receptor (Figure 2), albeit with 2–
3 orders of magnitude less potency than the cAMP response
(Table 1). No significant difference in IP1 accumulation was
Characterization of R181C, V266A and M311V V2R
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observed for the V266A receptor compared to wild-type, whereas
for the M311V receptor the potency of AVP was markedly
reduced (37-fold). Notably AVP failed to increase IP1 levels in cells
expressing R181C V2R, even at the highest dose tested (Figure 2).
Effect of V2R mutation on b-arrestin interaction
We next examined the ability of V2R/Rluc8 to interact with b-
arrestin in response to AVP stimulation, using a previously
validated BRET assay [13] to generate real-time kinetic profiles in
both HEK293FT and COS7 cells with multiple doses of AVP
(Figure 3). AVP caused a robust dose-dependent increase in BRET
signal for both wild-type and V266A V2R (Figures 3 and 4, and
Table 2), indicative of b-arrestin recruitment to the activated
receptor. In contrast, the R181C mutant was unable to recruit b-
arrestin at any dose tested, whereas the M311V receptor showed a
marked reduction in both the efficacy (,65% reduction) and
potency (23-fold decrease; Table 2) of AVP. The kinetic profile
with M311V V2R was also distinct from that of the wild-type
receptor (Figure 3), consistent with reduced temporal stability of
the receptor-arrestin complex [28]. Importantly, basal BRET
ratios for wild-type and mutant V2Rs were comparable (Table 2),
indicating that these mutations do not increase coupling to b-
arrestin in the absence of ligand.
Comparison of wild-type and mutant V2R cell surface
expression
The majority of disease-causing mutations of the V2R exhibit a
reduced ability to traffic to the plasma membrane [2]. To test for
this possibility, we examined cell surface expression using a
previously validated semi-automated imaging assay [32,33]. COS7
cells expressing wild-type and mutant HA-tagged receptors were
stained, initially as live intact cells, and cell surface expression
determined by immunofluorescence (Figure 5). As shown, cell
surface expression of each of the mutant V2Rs was comparable to
wild-type. This, together with the comparable maximal ligand-
induced cAMP responses (Figure 1), suggests that these receptors
retain their ability to traffic to the plasma membrane. Further-
more, in both HEK293FT and COS7 cells, V2R/Rluc8
luminescence was not significantly different between wild-type
and mutant V2Rs, indicating that these mutations also do not
Figure 1. AVP-induced cAMP accumulation. Transfected HEK293FT cells (A, B) or COS7 cells (C) expressing either wild-type or mutant HA-
tagged V2R (A, C) or Rluc8-tagged V2R (B), were treated for 30 minutes with stimulation buffer containing 0.5 mM IBMX together with the indicated
concentrations of AVP or 50 mM forskolin. Following additions, cells were lysed and cAMP accumulation measured by HTRF. Data shown are HTRF
signal in arbitrary units (AU) normalized to the forskolin response. Results shown are the mean 6 SEM of 3 independent experiments.
doi:10.1371/journal.pone.0065885.g001
Table 1. pEC50 values and fold change in EC50 for AVP-induced cAMP and IP1 accumulation.
cAMP IP1
HEK293FT COS7 HEK293FT
HA-V2R V2R/Rluc8 HA-V2R HA-V2R
pEC50 Fold change pEC50
Fold
change pEC50
Fold
change pEC50
Fold
change
wt 10.5760.27 1.0 10.7860.14 1.0 10.1060.17 1.0 7.8260.13 1.0
R181C 7.9460.20*,** 427 7.9360.16*,** 708 6.5160.07*,**,*** 3891 ND ND
V266A 10.7660.06 0.6 10.8460.20 0.9 10.3160.15 0.6 7.9760.13 0.7
M311V 9.1160.07* 28.8 9.3460.12* 27.5 8.3260.25* 60.3 6.2560.13* 37.2
Transfected HEK293FT or COS7 cells were treated as per Figure 1 or 2. Data shown are the pEC50 values for AVP treatment (30 min) and are the mean 6 SEM of 3 or 5
independent experiments for cAMP and IP1 respectively. Fold change from the wild-type receptor EC50 data are given in adjacent columns.
*, significantly different to the corresponding wild-type receptor in the same cell line (P,0.001);
**, significantly different to M311V in the same cell line (P,0.01 for HA-V2R in HEK293FT and P,0.001 for V2R/Rluc8 in HEK293FT and HA-V2R in COS7);
***, significantly different to R181C HA-V2R in HEK293FT cells. ND=Not determined.
doi:10.1371/journal.pone.0065885.t001
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compromise overall receptor expression in each cell line (Table 3).
Although no difference in expression was observed within each cell
line, Rluc8-tagged receptor expression in COS7 cells was
significantly lower than in HEK293FT cells (Table 3). This lower
expression in COS7 cells is likely to explain the lower absolute
cAMP accumulation (Figure 1) and BRET signals (Figures 3 and
4), and may contribute to the lower AVP potency with R181C
V2R in COS7 compared to HEK293FT cells (Table 1).
Determination of receptor/ubiquitin interaction
The V2R undergoes agonist-induced conjugation of ubiquitin
to K268, which regulates receptor degradation [38]. In a final
series of experiments, we used a BRET assay of ubiquitin
recruitment [29] to investigate the possibility that V266A mutation
influences V2R ubiquitination, and thereby contributes to
pathogenesis. As expected, AVP increased BRET between wild-
type V2R/Rluc8 and ubiquitin/Venus in a dose-dependent
manner (pEC50: 7.8360.14) in HEK293FT cells (Figure 6).
Notably, the V266A mutant displayed a very similar AVP dose-
response curve (pEC50: 7.7260.06) compared to the wild-type
receptor. In contrast, the AVP potency with M311V V2R was
significantly (P,0.001) lower (pEC50: 6.5760.01) and that with
R181C V2R was too low to determine, as the curve did not
plateau (Figure 6).
Discussion
In this study we have characterized the molecular pharmacol-
ogy of three V2R variants from patients with differing disease
phenotypes. Two of the mutants were previously described
(R181C [19–25], and M311V [25]), and are reported to cause
complete and partial NDI respectively [25]. The third variant
(V266A) was found in a patient with a diagnosis consistent with
NSIAD, including chronic hyponatremia and undetectable ADH
levels. Using a number of functional assays we have confirmed that
the M311V mutant retains greater activity than R181C V2R,
consistent with the milder phenotype of NDI associated with this
mutation. In contrast, the V266A V2R appears functionally
identical to the wild-type receptor in all aspects of pharmacology
tested by us, and others [26]. It is possible that the V266A
variation requires additional modifying events, such as compound
changes in G protein, b-arrestin or other proteins important for
V2R signaling or regulation, for the phenotype to become
penetrant. However, we feel it is more likely that the V266A
change represents a rare silent polymorphism, with the causative
mutation being in another protein such as aquaporin-2. This case
underscores the importance of functional testing of genetic
variants discovered during clinical investigations.
Figure 2. AVP-induced IP1 accumulation. Transfected HEK293FT
cells expressing either wild-type or mutant HA-tagged V2R were treated
for 30 minutes with the indicated concentrations of AVP. Following
additions, cells were lysed and IP1 accumulation measured by HTRF.
Data shown are HTRF signal in arbitrary units (AU) normalized to the
wild-type receptor response. Results shown are the mean 6 SEM of 5
independent experiments.
doi:10.1371/journal.pone.0065885.g002
Figure 3. Effect of V2R mutations on the kinetics of AVP-
induced b-arrestin2/Venus recruitment. Extended BRET kinetic
profiles were generated with HEK293FT cells (A, B, C, D) or COS7 cells
(E, F, G, H) expressing b-arrestin2/Venus with wild-type, R181C, V266A,
or M311V V2R/Rluc8, as indicated. Cells were treated with indicated
concentrations of AVP and kinetic BRET responses recorded. Data
shown are the mean 6 SEM of 3 independent experiments.
doi:10.1371/journal.pone.0065885.g003
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Of the over 200 mutations of the V2R that have been reported,
at least 100 are missense mutations [8]. The majority of these
mutated receptors fail to traffic to the cell surface and are retained
in the endoplasmic reticulum [2]. In this regard, treatment with
membrane permeable pharmacochaperones that are thought to
aid in folding and functionally rescue mutant receptors may be of
therapeutic benefit [18]. However, a number of V2R mutants are
properly targeted to the plasma membrane, but are unable to bind
AVP or signal though Gs protein to increase cAMP [2]. In this
study, it appears that all three V2R variants were able to
adequately traffic to the plasma membrane, as evidenced by HA-
V2R staining and maximal cAMP signaling comparable to wild-
type in response to AVP treatment. As such, both R181C and
M311V mutants appear to be defective in ligand binding or
signaling. Indeed, although to our knowledge no high-resolution
structure of the V2R exists, 3D homology modeling indicates that
both R181 and M311 are key residues for AVP binding [39].
The R181C mutation is present within the second extracellular
loop, proximal to the plasma membrane [25]. Prior reports
indicate that cysteine residue substitutions within these regions
(R181C, G185C, R202C, R203C, Y205C) cause inactivating
mutations and NDI [8,25]. The V2R contains a conserved
disulfide bond between C112 of the first extracellular loop and
C192 of the second extracellular loop. Hence, any additional
cysteine residue may interfere with formation of the conserved
disulfide bond and/or introduce different deleterious disulfide
bonds [40,41].
Previous studies also report that the R181C mutant correctly
traffics to the plasma membrane but has a markedly reduced
capacity for AVP binding, and reduced AVP-induced cAMP
production, with an approximate 1000-fold [20], 860-fold [25], or
100-fold [22] shift in potency. We observed similarly dramatic
decreases in potency for cAMP accumulation in the two cell lines
tested. However, the previous reports did not investigate IP1
accumulation or b-arrestin coupling for this mutant, and although
high doses of AVP caused maximal cAMP responses (Figure 1), no
IP1 accumulation was measured at any dose tested in HEK293FT
cells (Figure 2). Similarly, no ligand-induced interaction between
R181C V2R and b-arrestin was observed at any dose in either
HEK293FT or COS7 cells (Figures 3 and 4). Consequently, we
suggest that R181C V2R may be a Gs protein-biased receptor,
albeit one for which AVP exhibits low potency compared to wild-
type V2R for Gs coupling. Furthermore, with the M311V V2R,
partial agonism was apparent for IP1 accumulation and b-arrestin
recruitment not just a lower potency as for cAMP signaling.
Although, the wild-type receptor itself exhibits approximately 2–3
orders of magnitude lower potency for AVP when signaling to IP1
and recruiting b-arrestin (pEC50 7.82 and 8.31 respectively;
Figure 4. Dose-response curves for the effect of V2R mutations on AVP-induced b-arrestin2/Venus recruitment. BRET dose-response
data were generated with HEK293FT cells (A) or COS7 cells (B) expressing b-arrestin2/Venus with wild-type, R181C, V266A, or M311V V2R/Rluc8. Data
shown are the ligand-induced BRET response at 60 minutes post AVP treatment, and are the mean 6 SEM of 3 independent experiments.
doi:10.1371/journal.pone.0065885.g004
Table 2. pEC50 values, fold change in EC50, and difference in basal BRET ratio compared to wild-type for AVP-induced b-arrestin2/
Venus recruitment to V2R/Rluc8.
HEK293FT COS7 HEK293FT COS7
pEC50 Fold change pEC50 Fold change Difference in basal BRET ratio compared to wild-type
wt 8.3160.21 1.0 8.5460.02 1.0 0.00060.008 0.00060.009
R181C ND ND ND ND 0.01460.008 0.00060.003
V266A 8.2460.19 1.2 8.4560.05 1.2 0.02060.012 20.00760.006
M311V 6.9660.04* 22.4 7.1860.23* 22.9 0.00460.015 0.01460.008
Transfected HEK293FT or COS7 cells were treated as per Figure 3. Data shown are the pEC50 values for AVP treatment (60 min), fold change from the wild-type EC50, and
the BRET ratio for each receptor minus the mean BRET ratio for wild-type receptor (both prior to addition of agonist). Data are the mean 6 SEM of 3 independent
experiments.
*, significantly different to the corresponding wild-type receptor in the same cell line (P,0.001). ND=Not determined.
doi:10.1371/journal.pone.0065885.t002
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Table 1 and 2) compared to cAMP signaling (pEC50 10.57), if the
R181C receptor maintained the shift observed in the cAMP assay
(427-fold difference from wild-type in HEK293FT cells) one would
expect to detect clear IP1 and b-arrestin responses at the highest
doses of AVP tested, with theoretical pEC50s of approximately 5.2
and 5.7 for IP1 and b-arrestin respectively. However, no such
responses are seen, suggesting a degree of Gs protein bias.
Importantly as well, the potency shift for the M311V mutant is
similar for IP1 and b-arrestin compared to cAMP, indicating a
lack of bias in terms of potency for M311V, in contrast to R181C.
Various GPCRs have been engineered to induce signaling bias,
including the dopamine D2 receptor [42], b2 adrenergic receptor
[43], and designer receptors exclusively activated by designer
drugs (DREADDs) [44,45]. However naturally occurring muta-
tions resulting in signaling bias are rare in the literature [46],
particularly when the bias is towards G protein signaling. Notably,
a Gs-biased thyrotropin receptor mutant has been reported [47].
This mutant is correctly expressed at the cell surface, able to
increase intracellular cAMP, but markedly defective in inositol
phosphate generation, resulting in an imbalance between iodide
trapping (Gs-dependent) and iodide organification (Gq-dependent)
[47]. Furthermore, a comprehensive examination of signaling-
biased mutants was recently completed for the calcium-sensing
receptor [48]. A number of biased synthetic ligands have been
reported for the V2R [49], and protean agonism [50] by non-
peptide antagonists was recently revealed using two V2R mutants
(Ser-333del and Y128S) [51], highlighting the diverse pharmacol-
ogy arising from different conformational states of the V2R.
As a result of the likely structural changes in disulfide bond
formation and therefore receptor configuration discussed above,
we hypothesize that the R181C mutation stabilizes a conformation
even less suitable for Gq-coupling and b-arrestin interaction than
Gs-coupling. This bias in ligand-induced receptor function in the
absence of notable constitutive activity differs from the bias seen by
Carpentier et al. with the F229V mutation, which resulted in
constitutive cAMP signaling without constitutive b-arrestin
recruitment, the latter function being similar to wild-type [9].
Collectively, these findings illustrate that alterations in receptor
conformation due to mutation can have different effects depending
on the function assessed, thus highlighting the value of compre-
hensively profiling multiple functions.
Following agonist stimulation the human V2R is ubiquitinated
at K268, which mediates agonist-induced receptor degradation
[38]. Hence we used a BRET-based assay of receptor-ubiquitin
Figure 5. Quantification of HA-V2R cell surface expression by automated imaging. COS7 cells expressing HA-V2R constructs were stained
with anti-HA antibody, initially as live intact cells, prior to image acquisition and analysis using an IN Cell Analyzer 1000. Data shown are an Expression
Index defined as the percentage of positive cells (.10% above background) multiplied by their mean fluorescence intensity (A), and are the mean6
SEM of 3 experiments. Representative images of nuclei stained with Hoechst 33258 (B), cell surface HA-V2R stain (C), and automated image
segmentation (D) are shown. As illustrated in (D), IN Cell Analyzer software was used to define perimeters of nuclei (blue) and cells (green or red) with
a filter to distinguish cells in which staining was .10% above background (green perimeters (1)) or ,10% above background (red perimeters (0)).
Each of the image panels corresponds to a width of 250 mm and represents approximately 1/10th of the area captured in each field of view.
doi:10.1371/journal.pone.0065885.g005
Table 3. Relative V2R/Rluc8 expression in live cells.
HEK293FT COS7
RLU % wt RLU % wt
wt 143394625126 100618 876863321 100638
R181C 152886619465 107614 938063250 107637
V266A 148174622523 103616 637961601 73618
M311V 129322617097 90612 505761763 58620
HEK293FT or COS7 cells were transfected with the indicated V2R/Rluc8
constructs together with b-arrestin2/Venus. Luminescence was measured in
triplicate wells after 2 h pre-treatment with 30 mM EnduRen, as part of the
extended BRET kinetic assays (Figure 3). Data shown are the mean 6 SEM of 3–
7 independent experiments. RLU = relative light units. Luminescence intensity
in cells not expressing Rluc8 was 30–150 RLU.
doi:10.1371/journal.pone.0065885.t003
Figure 6. Effect of V2R mutations on AVP-induced ubiquitin/
Venus recruitment. HEK293FT cells expressing ubiquitin/Venus and
wild-type or mutant V2R/Rluc8 constructs were stimulated with the
indicated concentrations of AVP for 120 min. Data shown are the mean
6 SEM of 4 independent experiments.
doi:10.1371/journal.pone.0065885.g006
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interaction to test our mutant receptors for defects in this pathway.
For ubiquitin recruitment to R181C and M311V, the rank order
of potency for AVP was comparable to the data obtained for
intracellular cAMP accumulation (Figure 1). Interestingly, R181C
retained some ability to recruit ubiquitin to the activated receptor,
despite an earlier report that b-arrestin is required for this
interaction [38]. Accordingly, we suggest that alternative mech-
anisms may be in place, or that a very weak/transient interaction
of b-arrestin may suffice. Note that as both receptor-arrestin and
receptor-ubiquitin assays utilized the same assay platform, it seems
unlikely that our ability to detect R181C V2R ubiquitination but
not b-arrestin recruitment is due to assay sensitivity.
Notably, the V266A mutation had no effect on ubiquitin
interaction, in addition to wild-type-like cAMP and b-arrestin
responses. The V266A variant has been previously reported in
combination with a missense mutation (W200X/V266A) in a
patient with NDI [26]. Here the authors also concluded that the
V266A mutation has no functional consequence (as determined by
radioligand binding, cAMP assay and cell surface receptor
expression by ELISA), with the W200X truncation being the
primary cause of NDI in that case [26]. The lack of any observable
effect, shown herein and by Schulz et al, suggests that the V266A
mutation may be a genetic polymorphism; one of 21 such AVPR2
gene variants reported [8]. It is important to note that the patient
herein has been diagnosed with NSIAD, not NDI as in the prior
study, although presumably the W200X truncation dominates
over the V266A mutation when combined. Typically, NSIAD
results from constitutive V2R activity (e.g. as shown for F229V [9]
and R137C/L [6,13]). However, here we find no evidence of
constitutive activity. Hence, more detailed genetic studies are
required to determine the precise cause of NSIAD in this patient, a
starting point being aquaporin-2.
Interestingly, Zhong and colleagues engineered a V266K
mutant V2R, in order to investigate potential Gq coupling
properties, as a K residue at this position in the oxytocin receptor
is important for IP3 generation [52]. Again, the authors report
that this mutation does not influence AVP binding affinity or
cAMP production. A small change (1.5 fold) in IP3 generation was
reported but the authors conclude that is negligible when
compared to the large (4 fold) change observed when the V2R is
engineered to include the entire oxytocin receptor third intracel-
lular loop region [52]. Notably, we found no significant difference
in IP1 accumulation for the V266A mutant (Figure 2).
In conclusion, we could find no functional difference between
wild-type and V266A V2R, hence the etiology of NSIAD in this
patient remains unknown. We found that the M311V mutant
V2R retains greater activity than R181C V2R, with respect to b-
arrestin recruitment and receptor ubiquitination as well as cAMP
and IP1 production, consistent with the milder phenotype of NDI
associated with this mutant. Furthermore, our analysis of the
R181C V2R suggests that it is a Gs protein-biased receptor. As
recently discussed by Carpentier at al. [9], distinct mutations can
result in distinct effects on different aspects of receptor pharma-
cology, and we have illustrated this in terms of both partial
(M311V) and biased (R181C) agonism. Importantly, a clearer
understanding of the effects of clinical mutations at the molecular
pharmacological level can inform both drug discovery and patient
treatment, with the tailoring of pharmaceuticals to individuals
based on their receptor signaling profiles.
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